Research
Hormonal
GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) and SGLT-2 inhibitors are preferred medications for obesity management in patients with cardiovascular or metabolic risk, as they promote weight loss and improve cardiovascular health.
If you have obesity and diabetes or heart disease risk, ask your doctor about GLP-1 agonists (like semaglutide) or SGLT-2 inhibitors. These medications help you lose weight and protect your heart, unlike some other diabetes drugs that might cause weight gain.
GoodSupportsHIGH confidence
Management of T2DM should focus on optimising diabetes medications which promote weight loss, including GLP-1 agonists (Ozempic 1 mg – semaglutide), SGLT-2 inhibitors and metformin... SGLT-2 inhibitors and GLP-1 receptor agonists consistently show improvements in cardiovascular health
Why this rating
Cited from clinical guidelines and studies referenced in the review.
Source
Clinical evaluation of patients living with obesity
Laurence J. Dobbie et al. · Internal and Emergency Medicine · 2023
DOI 10.1007/s11739-023-03263-2
narrative_reviewCited 13×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity is a chronic disease requiring comprehensive clinical evaluation and staging (e.g., EOSS, Kings criteria) rather than reliance on BMI alone, as BMI has low sensitivity for adiposity and fails to capture complication risk.Good
- Metabolic health status (MHO vs. MUO) is a better predictor of long-term cardiovascular risk and mortality than BMI alone, with metabolically unhealthy obesity (MUO) requiring prompt intervention.Good
- Weight loss of 2.5-15% improves glycemic control in Type 2 Diabetes, while 5-10% weight loss may prevent knee pain in obesity-related osteoarthritis.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →